Shin-Ichiro Fujii
Overview
Explore the profile of Shin-Ichiro Fujii including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
3679
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Crucial immunological roles of the invasion front in innate and adaptive immunity in cervical cancer
Hirahara Y, Shimizu K, Yamasaki S, Iyoda T, Ueda S, Sato S, et al.
Br J Cancer
. 2024 Oct;
131(11):1762-1774.
PMID: 39472714
Background: The immunostimulatory actions of innate and adaptive immune responses play a crucial role in the cancer-immunity cycle. Although cervical cancer (CC) exhibits a high recurrence rate, the relation with...
2.
Okada M, Yamasaki S, Nakazato H, Hirahara Y, Ishibashi T, Kawamura M, et al.
Cancer Res
. 2024 Sep;
84(17):2792-2805.
PMID: 39228255
Neoantigen-based immunotherapy is an attractive potential treatment for previously intractable tumors. To effectively broaden the application of this approach, stringent biomarkers are crucial to identify responsive patients. ARID1A, a frequently...
3.
NKT-Licensed In Vivo Dendritic Cell-Based Immunotherapy as Cellular Immunodrugs for Cancer Treatment
Fujii S, Shimizu K
Crit Rev Oncog
. 2024 Feb;
29(1):45-61.
PMID: 38421713
With the advent of new therapies, immunotherapy has gained attention as a critical modality. After the discovery of the natural killer T (NKT) cells ligand, ex vivo cultured dendritic cells...
4.
Yamasaki S, Shimizu K, Fujii S
Front Immunol
. 2024 Feb;
15:1345037.
PMID: 38361934
Introduction: Cancer is categorized into two types based on the microenvironment: cold and hot tumors. The former is challenging to stimulate through immunity. The immunogenicity of cancer relies on the...
5.
Iyoda T, Shimizu K, Endo T, Watanabe T, Taniuchi I, Aoshima H, et al.
Commun Biol
. 2023 Oct;
6(1):1070.
PMID: 37903859
After activation, some invariant natural killer T (iNKT) cells are differentiated into Klrg1 long-lived effector NKT1 cells. However, the regulation from the effector phase to the memory phase has not...
6.
Shimizu K, Ueda S, Kawamura M, Aoshima H, Satoh M, Nakabayashi J, et al.
J Immunother Cancer
. 2023 Jul;
11(7).
PMID: 37400134
Background: A key to success of cancer immunotherapy is the amplification and sustenance of various effector cells. The hallmark of prominent antitumor T cells is their long-term effector function. Although...
7.
Okada M, Shimizu K, Nakazato H, Yamasaki S, Fujii S
Mol Ther Methods Clin Dev
. 2023 Jun;
29:541-555.
PMID: 37359417
Multiple myeloma (MM) remains an incurable hematological neoplasm. Neoantigen-specific T cell receptor (TCR)-engineered T (TCR-T) cell therapy is a potential alternative treatment. Particularly, TCRs derived from a third-party donor may...
8.
Iyoda T, Yamasaki S, Ueda S, Shimizu K, Fujii S
Biomolecules
. 2023 Feb;
13(2).
PMID: 36830717
Both natural killer T (NKT) and natural killer (NK) cells are innate cytotoxic lymphoid cells that produce inflammatory cytokines and chemokines, and their role in the innate immune response to...
9.
Iyoda T, Shimizu K, Kawamura M, Shinga J, Watanabe T, Fukunaga K, et al.
Immunohorizons
. 2023 Jan;
7(1):1-16.
PMID: 36637516
NK cells are major effector cells involved in the elimination of early tumors and prevent metastasis. They often have an impaired function in patients with cancer. Preclinical studies have demonstrated...
10.
Fujii S, Yamasaki S, Iyoda T, Shimizu K
Inflamm Regen
. 2022 Nov;
42(1):50.
PMID: 36447262
Coronaviruses regularly cause outbreaks of zoonotic diseases characterized by severe pneumonia. The new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused the global pandemic disease COVID-19 that began...